RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionCD8 T cells play a pivotal role in the antitumor immune response by directly targeting and eliminating tumor cells expressing tumor antigens.However, tumor suppression by tumor-reactive CD8 T cells can be hindered by T cell exhaustion or dysfunction, in which continuous antigen stimulation along with the signals from immune checkpoint molecules, gradually impairs T cell activity.
Despite the clinical success of immune checkpoint inhibitors (ICIs), the response rate in many cancer patients remains still low. Also, therapeutic strategies to increase the activity of tumor-reactive T cells are ineffective in situations where tumor antigen expression is limited, emphasizing the demand for innovative immunotherapies with improved efficacy, like ONCY's drug platform in pelareorep, for the treatment of multiple cancers.